Pioneering Innovations in Cancer Drug Development

11:00 AM - 12:00 PM (EST), Tuesday, February 16, 2021
Frequently altered driver genes in cancer, such as RAS, TP53 and MYC, are attractive targets for cancer treatments. However, these genes have been proven difficult to target and remain a key challenge in cancer research. Innovation is gravely needed and successes with “undruggable” candidates going into later stage studies is driving investor interest, with new companies closing up to $100m for a Series A. Join officers from leading companies as they conduct a deep-dive on the most exciting development, while also acknowledging the obstacles, as the industry considers what the future holds for this important area of research.
Moderator
photo
Managing Director, Equity Research, Biotech
Truist Securities
Speakers
photo
VP, Global Development
Amgen Inc.
photo
Managing Director, Equity Research, Biotech
Truist Securities
photo
CEO
Boundless Bio Inc.
photo
Director, Emerging Technology & Innovation - Cambridge
Eli Lilly and Company
photo
President & CSO
Kezar Life Sciences
photo
Managing Director
Vertex Ventures